Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.

MLA

Boyer, Michael, et al. “Pembrolizumab with Platinum-Based Chemotherapy with or without Epacadostat as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer: A Randomized, Partially Double-Blind, Placebo-Controlled Phase II Study.” BMC Cancer, vol. 23, no. Suppl 1, July 2024, p. 1250. EBSCOhost, https://doi.org/10.1186/s12885-022-10427-4.

APA

Boyer, M., Hui, R., Urban, D., Clingan, P., Su, W.-C., Devaux, C., Gadgeel, S., Garassino, M., Leopold, L., Daniel, J., Munteanu, M. C., Samkari, A., Luo, Y., & Abreu, D. R. (2024). Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer, 23(Suppl 1), 1250. https://doi.org/10.1186/s12885-022-10427-4

Chicago

Boyer, Michael, Rina Hui, Damien Urban, Philip Clingan, Wu-Chou Su, Celine Devaux, Shirish Gadgeel, et al. 2024. “Pembrolizumab with Platinum-Based Chemotherapy with or without Epacadostat as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer: A Randomized, Partially Double-Blind, Placebo-Controlled Phase II Study.” BMC Cancer 23 (Suppl 1): 1250. doi:10.1186/s12885-022-10427-4.